Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
CASI 
CASI Pharmaceuticals Inc (CASI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: CASI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 16.21% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 14.87M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 1 | Beta 0.85 | 52 Weeks Range 0.93 - 3.97 | Updated Date 12/7/2025 |
52 Weeks Range 0.93 - 3.97 | Updated Date 12/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.02 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-11-14 | When - | Estimate -0.6 | Actual -0.68 |
Profitability
Profit Margin -183.96% | Operating Margin (TTM) -333.14% |
Management Effectiveness
Return on Assets (TTM) -61.8% | Return on Equity (TTM) -1094.5% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 33898396 | Price to Sales(TTM) 0.55 |
Enterprise Value 33898396 | Price to Sales(TTM) 0.55 | ||
Enterprise Value to Revenue 1.26 | Enterprise Value to EBITDA 0.07 | Shares Outstanding 15492781 | Shares Floating 12321772 |
Shares Outstanding 15492781 | Shares Floating 12321772 | ||
Percent Insiders 54.76 | Percent Institutions 17.15 |
Upturn AI SWOT
CASI Pharmaceuticals Inc
Company Overview
History and Background
CASI Pharmaceuticals Inc. was founded in 1995 and has undergone several transformations. Initially focused on biopharmaceutical development, the company has shifted its strategic direction to become a China-focused biopharmaceutical company. Significant milestones include the acquisition of exclusive rights to develop and commercialize innovative oncology and autoimmune drugs, as well as strategic partnerships aimed at expanding its pipeline and market reach within China.
Core Business Areas
- Oncology and Autoimmune Therapeutics Development: CASI Pharmaceuticals Inc. is primarily focused on the development and commercialization of innovative oncology and autoimmune therapeutics for the China market. This includes identifying, acquiring, and advancing promising drug candidates through clinical development and regulatory approval.
- Market Access and Commercialization in China: The company leverages its understanding of the Chinese regulatory landscape and market dynamics to bring its pipeline products to patients in China. This involves navigating clinical trials, seeking regulatory approvals from the NMPA, and establishing commercialization strategies.
Leadership and Structure
CASI Pharmaceuticals Inc. is led by a management team with experience in the pharmaceutical industry, particularly within the Chinese market. The organizational structure is designed to facilitate drug development, regulatory affairs, and commercial operations tailored to the specific needs of China.
Top Products and Market Share
Key Offerings
- Ezturolimab (CASI-002): Ezturolimab is a potential first-in-class antibody targeting PD-1, developed for the treatment of various types of cancer. Competitors in the PD-1 inhibitor market include established global players and emerging Chinese biopharmaceutical companies. Market share data for specific pipeline drugs in early development is not yet available.
- CNI-1491 (CASI-003): CNI-1491 is a novel small molecule drug candidate that has shown preclinical and early clinical activity in treating multiple solid tumors, including pancreatic cancer. This is a competitive space with various targeted therapies and immunotherapies. Market share data for specific pipeline drugs in early development is not yet available.
- Antroquinonol (CASI-007): Antroquinonol is a natural compound being developed for the treatment of certain types of cancer. It is in clinical trials for indications such as non-small cell lung cancer. Competitors include other small molecule inhibitors and immunotherapies. Market share data for specific pipeline drugs in early development is not yet available.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly in China, is characterized by rapid growth, increasing government support for innovation, and a rising demand for advanced healthcare solutions. The oncology and autoimmune disease markets are significant and growing segments due to aging populations and increasing disease prevalence.
Positioning
CASI Pharmaceuticals Inc. positions itself as a China-focused biopharmaceutical company dedicated to bringing innovative therapies to the Chinese market. Its competitive advantage lies in its understanding of the Chinese regulatory environment, its strategic partnerships, and its focus on therapeutic areas with high unmet medical needs.
Total Addressable Market (TAM)
The total addressable market for oncology and autoimmune therapeutics in China is substantial and projected to grow significantly in the coming years, driven by an expanding middle class, increased healthcare spending, and government initiatives to improve healthcare access. CASI Pharmaceuticals Inc. is positioned to capture a portion of this market by developing and commercializing targeted therapies for these indications.
Upturn SWOT Analysis
Strengths
- Focus on the large and growing Chinese biopharmaceutical market.
- Strategic partnerships and licensing agreements for promising drug candidates.
- Experienced management team with expertise in the Chinese market.
- Pipeline of innovative drug candidates in oncology and autoimmune diseases.
Weaknesses
- Reliance on a limited number of drug candidates in development.
- Potential challenges in clinical trial execution and regulatory approval in China.
- Limited track record of commercial success for its own developed products.
- Financing needs for ongoing research and development.
Opportunities
- Increasing government support for innovative drug development in China.
- Growing demand for advanced therapies for cancer and autoimmune diseases.
- Potential for strategic collaborations with larger pharmaceutical companies.
- Expansion of indications for existing pipeline drugs.
Threats
- Intense competition from both domestic and international biopharmaceutical companies.
- Uncertainty in clinical trial outcomes and regulatory approvals.
- Pricing pressures and reimbursement challenges in the Chinese market.
- Intellectual property challenges and patent expirations.
Competitors and Market Share
Key Competitors
- BeiGene Ltd. (BGNE)
- Innovent Biologics, Inc. (IVBXF)
- Jiangsu Hengrui Medicine Co., Ltd. (600276.SS)
- Zai Lab Limited (ZLAB)
Competitive Landscape
CASI Pharmaceuticals Inc. operates in a highly competitive landscape with larger, well-established players, as well as emerging biotech firms in China. Its advantage lies in its specific focus on certain therapeutic niches and its localized approach to the Chinese market. However, it faces challenges in competing with the extensive R&D resources, established commercial infrastructure, and larger product portfolios of its rivals.
Growth Trajectory and Initiatives
Historical Growth: Historically, CASI Pharmaceuticals Inc.'s growth has been tied to its strategic shifts and the acquisition of new drug candidates. The company has focused on building its pipeline and establishing its presence in the Chinese market.
Future Projections: Future growth projections are contingent on the successful progression of its pipeline drugs through clinical trials and regulatory approval, as well as effective commercialization strategies in China. Analyst estimates would reflect the potential market size and success rates of its key assets.
Recent Initiatives: Recent initiatives likely include advancing clinical trials for its lead drug candidates, securing new partnerships or licensing deals, and preparing for regulatory submissions in China.
Summary
CASI Pharmaceuticals Inc. is a China-focused biopharmaceutical company with a pipeline of promising oncology and autoimmune drug candidates. Its strengths lie in its strategic focus on the growing Chinese market and potential for high unmet medical needs. However, it faces significant risks due to its developmental stage, reliance on clinical trial success, intense competition, and ongoing need for financing. Success hinges on navigating regulatory hurdles and achieving commercial viability for its lead assets.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Investor Relations Websites
- Financial Data Providers (e.g., Refinitiv, Bloomberg)
- Industry Research Reports
Disclaimers:
This analysis is based on publicly available information as of the last update and is for informational purposes only. It does not constitute financial advice. Investing in biopharmaceutical companies, especially those in the development stage, carries significant risks. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CASI Pharmaceuticals Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1996-06-11 | CEO & Director Mr. David A. Cory M.B.A., R.Ph. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 233 | |
Full time employees 233 | |||
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company's hematology/oncology assets in pipeline include CNCT19, an autologous CD19 CAR-T investigative product; BI-1206, an novel anti-Fc"RIIB antibody for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. It has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.